Geneva (Switzerland), March 28, 2017 : GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, including multiple sclerosis (MS), today provided access to research on human endogenous retroviruses (HERVs) and their impact on neurological pathologies.
Further information on :
https://www.geneuro.com/data/news/geneuro-pr-herv-disease-en-final-28032017.pdf
